Skip to main content Skip to main navigation menu Skip to site footer
International Journal of Clinical and Biomedical Research
Original Research Articles
Submitted: 2026-02-17
Published: 2026-02-21

EFFECT OF THREE MONTHS COURSE OF DAILY TERIPARATIDE INJECTION ON OSTEOPOROSIS IN A RURAL POPULATION: A ONE YEAR FOLLOW UP STUDY USING pDEXA

Department of Orthopaedics, Dr Balasaheb Vikhe Patil Rural Medical College, Loni, Maharashtra
Dr Shirsath DB
Department of Orthopaedics, Dr Balasaheb Vikhe Patil Rural Medical College, Loni, Maharashtra
Department of Orthopaedics, Dr Balasaheb Vikhe Patil Rural Medical College, Loni, Maharashtra
Teriparatide; Osteoporosis; Bone Mineral Density; pDEXA

Abstract

Osteoporosis continues to represent a significant public-health problem, especially in the rural setting, where access to the availability of sophisticated diagnosis and treatment options limited. Awareness, knowledge and long term consequences, and the importance of calcium supplementation are often inadequate among rural population. Additionally, inadequate finances are also a significant barrier towards patient compliance, which increases disease burden and the risk of fractures. The present study aim is to test the intervention on the effects of a three-month trial of daily intramuscular teriparatide (20µg) administered subcutaneously on the patients with osteoporosis in a rural community. Then treatment outcomes assessed using peripheral dual-energy X-ray absorptiometry (pDEXA; EXA 3000). The study patients with osteoporotic cracks in the spine were included people who experienced spinal fractures. Inj teriparatide intervention was administered three months daily as SC injections. Patients were followed by regular follow-up up to 3 months and pDEXA measurements at a year time. The findings of the study helped to improve the knowledge of teriparatide effectiveness for the treatment of osteoporosis in the rural population and provided evidence to support therapeutic interventions to develop feasible and effective osteoporosis management strategies.

References

  1. Dimai HP, Fahrleitner-Pammer A. Osteoporosis and fragility fractures: currently available pharmacological options and future directions. Best Pract Res Clin Rheumatol. 2022;36(3):101780.
  2. Chang CB, Yang RS, Huang WJ, Chou YC, Wen CJ, Huang TC, et al. Urban–rural differences in outcomes and management of vertebral fractures: a real-world observational study. J Formos Med Assoc. 2023;122(8):690-698.
  3. Salari N, Darvishi N, Bartina Y, Larti M, Kiaei A, Hemmati M, et al. Global prevalence of osteoporosis among older adults: a systematic review and meta-analysis. J Orthop Surg Res. 2021;16(1):669.
  4. Bhatia M, Dwivedi LK, Maurya P, Dawoodi S, Ahmed W, Jana S, et al. Gender and age differentials in prevalence and pattern of nine chronic diseases among older adults in India. J Clin Hypertens. 2025;27(5):e70069.
  5. Compston JE, McClung MR, Leslie WD. Osteoporosis. Lancet. 2019;393(10169):364-376.
  6. Curtis JR, Safford MM. Management of osteoporosis among the elderly with other chronic medical conditions. Drugs Aging. 2012;29(7):549-560.
  7. Johnell O, Kanis JA. Worldwide prevalence and disability associated with osteoporotic fractures. Osteoporos Int. 2006;17(12):1726-1733.
  8. Kanis JA, Borgstrom F, De Laet C, et al. Assessment of fracture risk. Osteoporos Int. 2005;16(6):581-589.
  9. Hernlund E, Svedbom A, Ivergård M, et al. Osteoporosis in the European Union. Arch Osteoporos. 2013;8:136.
  10. Yoshimura N, Muraki S, Oka H, et al. Prevalence of knee osteoarthritis, lumbar spondylosis, and osteoporosis in Japan. J Bone Miner Metab. 2009;27(5):620-628.
  11. Nakatani H. Population aging in Japan: policy transformation, sustainable development goals, universal health coverage, and social determinants of health. Glob Health Med. 2019;1(1):3-10.
  12. Guelman R, Sánchez A, Varsavsky M, Brun LR, García ML, Sarli M, et al. Effect of teriparatide on bone mineral density and bone markers in real life: Argentine experience. Int J Endocrinol. 2023;2023:9355672.
  13. Roy AN, Mazumdar I. Effects of teriparatide treatment on bone mineral density in patients with osteoporosis: a short-term dose-response study. Cureus. 2023;15(9):e45662.
  14. Teng GG, Curtis JR, Saag KG. Mortality and osteoporotic fractures: is the link causal and modifiable? Clin Exp Rheumatol. 2008;26(Suppl 51):S125-S137.
  15. Miller PD, Bolognese MA, Lewiecki EM, et al. Effect of teriparatide on bone mineral density. J Clin Endocrinol Metab. 2008;93(10):3785-3793.
  16. Medical Advisory Secretariat. Utilization of DXA bone mineral densitometry in Ontario: an evidence-based analysis. Ont Health Technol Assess Ser. 2006;6(20):1-180.
  17. Lindsay R, Krege JH, Marin F, Jin L, Stepan JJ. Teriparatide for osteoporosis: importance of the full course. Osteoporos Int. 2016;27(8):2395-2410.
  18. Ascenzi MG, Liao VP, Lee BM, Billi F, Zhou H, Lindsay R, et al. Parathyroid hormone improves cortical bone microstructure in postmenopausal osteoporosis. J Bone Miner Res. 2012;27(3):702-712.
  19. Neer RM, Arnaud CD, Zanchetta JR, et al. Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women. N Engl J Med. 2001;344(19):1434-1441.
  20. Miyauchi A, Matsumoto T, Sugimoto T, et al. Effects of teriparatide on bone mineral density and turnover in Japanese subjects. Osteoporos Int. 2010;21(5):843-851.
  21. Pietri M, Lucarini S. Orthopaedic treatment of fragility fractures. Clin Cases Miner Bone Metab. 2007;4(2):108-116.
  22. Leder BZ, Tsai JN, Uihlein AV, et al. Two years of teriparatide therapy. J Clin Endocrinol Metab. 2014;99(5):1694-1700.
  23. Cosman F, de Beur SJ, LeBoff MS, et al. Clinician’s guide to prevention and treatment of osteoporosis. Osteoporos Int. 2014;25(10):2359-2381.
  24. Black DM, Rosen CJ. Postmenopausal osteoporosis. N Engl J Med. 2016;374(3):254-262.

How to Cite

Dr.Ajinkya Surendra Girme, Dr. Shelke V, Dr Shirsath DB, & Dr Somani Ashish. (2026). EFFECT OF THREE MONTHS COURSE OF DAILY TERIPARATIDE INJECTION ON OSTEOPOROSIS IN A RURAL POPULATION: A ONE YEAR FOLLOW UP STUDY USING pDEXA . International Journal of Clinical and Biomedical Research, 11(1), 13–17. Retrieved from https://www.ijcbr.com/index.php/ijcbr/article/view/423